Human embryonic stem cell (hESC) derived cardiomyocytes are in the present study being used for testing drug-induced cardiotoxicity in a biosensor set-up. The design of an in vitro testing alternative provides a novel opportunity to surpass previous methods based on rodent cells or cell lines due to its significantly higher toxicological relevance. In this report we demonstrate how hESC-derived cardiomyocytes release detectable levels of two clinically decisive cardiac biomarkers, cardiac troponin T and fatty acid binding protein 3, when the cardiac cells are exposed to the well-known cardioactive drug compound, doxorubicin. The release is monitored by the immuno-biosensor technique surface plasmon resonance, particularly appropriate due to its capacity for parallel and high-throughput analysis in complex media. © 2010 Elsevier B.V.
CITATION STYLE
Andersson, H., Steel, D., Asp, J., Dahlenborg, K., Jonsson, M., Jeppsson, A., … Mandenius, C. F. (2010). Assaying cardiac biomarkers for toxicity testing using biosensing and cardiomyocytes derived from human embryonic stem cells. Journal of Biotechnology, 150(1), 175–181. https://doi.org/10.1016/j.jbiotec.2010.06.023
Mendeley helps you to discover research relevant for your work.